Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 12/20 | 1.00 |
| ▸ | ABL1 | P00519 | 10/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 10/20 | 1.00 |
| ▸ | PDGFRA | P16234 | 10/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 10/20 | 1.00 |
| ▸ | KIT | P10721 | 4/20 | 0.83 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.81 |
| ▸ | EGFR | P00533 | 10/20 | 0.81 |
| ▸ | WEE1 | P30291 | 4/20 | 0.81 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.81 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.81 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.81 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.75 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.75 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.75 |
| ▸ | STK25 | O00506 | 1/20 | 0.75 |
| ▸ | GAK | O14976 | 1/20 | 0.75 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.75 |
| ▸ | JAK2 | O60674 | 1/20 | 0.75 |
| ▸ | STK10 | O94804 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13859034 | 0.91 | SRC (0.83) | SRCABL1PDGFRBPDGFRAMAPK14 | |
| SCHEMBL2083696 | 0.91 | SRC (1.00) | SRCABL1PDGFRBPDGFRAMAPK14 | |
| SCHEMBL1249524 | 0.89 | FGFR1 (1.00) | SRCABL1PDGFRBPDGFRAMAPK14 | |
| SCHEMBL13498143 | 0.89 | FGFR1 (0.83) | SRCABL1PDGFRBPDGFRAMAPK14 | |
| SCHEMBL5762318 | 0.88 | FGFR1 (1.00) | SRCABL1PDGFRBPDGFRAMAPK14 | |
| SCHEMBL2082743 | 0.88 | FGFR1 (1.00) | SRCABL1PDGFRBPDGFRAMAPK14 | |
| SCHEMBL11939682 | 0.87 | FGFR1 (0.79) | SRCABL1PDGFRBPDGFRAMAPK14 | |
| SCHEMBL5763306 | 0.87 | FGFR1 (1.00) | SRCABL1PDGFRBPDGFRAMAPK14 | |
| SCHEMBL5764062 | 0.86 | FGFR1 (1.00) | SRCABL1PDGFRBPDGFRAMAPK14 | |
| SCHEMBL2083189 | 0.86 | SRC (1.00) | SRCABL1PDGFRBPDGFRAMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080220497-A1 | Modulation of protein functionalities | DECIPHERA PHARMACEUTICALS LLC | 2008-09-11 | — | — | US | claimed |
| EP-1907411-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | Deciphera Pharmaceuticals, LLC. (US) | 2008-04-09 | — | — | EP | claimed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | claimed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | claimed |
| WO-2007008917-A2 | MODULATION OF PROTEIN FUNCTIONALITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-01-18 | — | — | WO | claimed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | claimed |
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | M.D. ANDERSON CANCER CENTER (US) | 2012-11-29 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268809-B2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | EMORY UNIVERSITY (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2471529-A2 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | Emory University (US) | 2012-07-04 | — | — | EP | disclosed |
| US-8163756-B2 | For example,1-(3-t-butyl-1- (1,2,3,4-tetrahydro- isoquinolin-6-yl)-1H- pyrazol-5-yl)-3-(3- cyanophenyl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2364702-A2 | Kinase inhibitors for preventing or treating pathogen infection and method of use thereof | Emory University (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | EMORY UNIVERSITY (US) | 2010-09-30 | — | — | US | disclosed |
| WO-2008079460-A2 | TYROSINE KINASE INHIBITORS FOR PREVENTION OR TREATMENT OF INFECTION | EMORY UNIVERSITY (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| US-20050009849-A1 | Pyridopyrimidine kinase inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249122-A1 | Kinase Inhibitors for Preventing or Treating Pathogen Infection and Method of Use Thereof | MAP3K1, MAP3K2, MAP3K6 | SRC 149/4885ABL1 21/4885PDGFRB 1259/4885 |
| US-20050009849-A1 | Pyridopyrimidine kinase inhibitors | MAP3K1, MAP3K19, MAP3K20 | SRC 335/4885ABL1 8/4885PDGFRB 423/4885 |
| US-20120302565-A1 | KINASE INHIBITORS FOR PREVENTING OR TREATING PATHOGEN INFECTION AND METHOD OF USE THEREOF | MAP3K1, MAP3K2, MAP3K6 | SRC 149/4885ABL1 21/4885PDGFRB 1259/4885 |
| US-20080220497-A1 | Modulation of protein functionalities | C1QBP, SERPINA6, CD2BP2 | SRC 2604/4885ABL1 3158/4885PDGFRB 3462/4885 |
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | SRC 9/4885ABL1 1/4885PDGFRB 16/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | SRC 69/4885ABL1 20/4885PDGFRB 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.